{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:05:16Z","timestamp":1736226316468,"version":"3.32.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41440-024-01986-z","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T10:45:06Z","timestamp":1731581106000},"page":"425-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antihypertensive combinations: mind the potassium"],"prefix":"10.1038","volume":"48","author":[{"given":"Shigeru","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"1986_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1986_CR2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043\u201352.","journal-title":"Lancet"},{"key":"1986_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2024.18080","volume":"332","author":"DB Ojji","year":"2024","unstructured":"Ojji DB, Salam A, Sani MU, Ogah OS, Schutte AE, Huffman MD, et al. Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial. JAMA. 2024;332:1070\u20139.","journal-title":"JAMA"},{"key":"1986_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jama.2023.3322","volume":"329","author":"J Sundstrom","year":"2023","unstructured":"Sundstrom J, Lind L, Nowrouzi S, Hagstrom E, Held C, Lytsy P, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. JAMA. 2023;329:1160\u20139.","journal-title":"JAMA"},{"key":"1986_CR5","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"1986_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"1986_CR7","doi-asserted-by":"publisher","unstructured":"Hisamatsu T, Kogure M, Tabara Y, Hozawa A, Sakima A, Tsuchihashi T, et al. Practical use and target value of urine sodium-to-potassium ratio in assessment of hypertension risk for Japanese: Consensus Statement by the Japanese Society of Hypertension Working Group on Urine Sodium-to-Potassium Ratio. Hypertens Res. 2024. https:\/\/doi.org\/10.1038\/s41440-024-01861-x.","DOI":"10.1038\/s41440-024-01861-x"},{"key":"1986_CR8","doi-asserted-by":"publisher","unstructured":"Al-Janabi FLM, Moussa F, Taleb S, Leutscher PDC, Sondergaard MM, Melgaard D, et al. Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy - a retrospective register-based study. Hypertens Res. 2024. https:\/\/doi.org\/10.1038\/s41440-024-01894-2.","DOI":"10.1038\/s41440-024-01894-2"},{"key":"1986_CR9","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","volume":"43","author":"AK Pandey","year":"2022","unstructured":"Pandey AK, Bhatt DL, Cosentino F, Marx N, Rotstein O, Pitt B, et al. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J. 2022;43:2931\u201345.","journal-title":"Eur Heart J"},{"key":"1986_CR10","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1056\/NEJM198312083092303","volume":"309","author":"MJ Brown","year":"1983","unstructured":"Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983;309:1414\u20139.","journal-title":"N Engl J Med"},{"key":"1986_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2265.2002.01613.x","volume":"57","author":"C Seifarth","year":"2002","unstructured":"Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol. 2002;57:457\u201365.","journal-title":"Clin Endocrinol"},{"key":"1986_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.107.087577","volume":"50","author":"SM Kim","year":"2007","unstructured":"Kim SM, Chen L, Faulhaber-Walter R, Oppermann M, Huang Y, Mizel D, et al. Regulation of renin secretion and expression in mice deficient in beta1- and beta2-adrenergic receptors. Hypertension. 2007;50:103\u20139.","journal-title":"Hypertension"},{"key":"1986_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"1986_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33:225\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"1986_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.119.14223","volume":"75","author":"ML Krogager","year":"2020","unstructured":"Krogager ML, Mortensen RN, Lund PE, Boggild H, Hansen SM, Kragholm K, et al. Risk of Developing Hypokalemia in Patients With Hypertension Treated With Combination Antihypertensive Therapy. Hypertension. 2020;75:966\u201372.","journal-title":"Hypertension"},{"key":"1986_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2215\/CJN.01730215","volume":"11","author":"J Luo","year":"2016","unstructured":"Luo J, Brunelli SM, Jensen DE, Yang A. Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. Clin J Am Soc Nephrol. 2016;11:90\u2013100.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1986_CR17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney Int Rep. 2019;4:1248\u201360.","journal-title":"Kidney Int Rep"},{"key":"1986_CR18","doi-asserted-by":"publisher","first-page":"e078483","DOI":"10.1136\/bmj-2023-078483","volume":"385","author":"EL Fu","year":"2024","unstructured":"Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ. 2024;385:e078483.","journal-title":"BMJ"},{"key":"1986_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamainternmed.2024.3806","volume":"184","author":"T Huang","year":"2024","unstructured":"Huang T, Bosi A, Faucon AL, Grams ME, Sjolander A, Fu EL, et al. GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes. JAMA Intern Med. 2024;184:1195\u20131203.","journal-title":"JAMA Intern Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01986-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01986-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01986-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:41:10Z","timestamp":1736138470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01986-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01986-z","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"type":"print","value":"0916-9636"},{"type":"electronic","value":"1348-4214"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author received personal fees and\/or research funding from AstraZeneca, Bayer, and Daiichi-Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}